Putative COVID-19 therapies imatinib, lopinavir, ritonavir, and ivermectin cause hair cell damage: A targeted screen in the zebrafish lateral line

The biomedical community is rapidly developing COVID-19 drugs to bring much-need therapies to market, with over 900 drugs and drug combinations currently in clinical trials. While this pace of drug development is necessary, the risk of producing therapies with significant side-effects is also increa...

Descripción completa

Detalles Bibliográficos
Autores principales: Coffin, Allison B., Dale, Emily, Doppenberg, Emilee, Fearington, Forrest, Hayward, Tamasen, Hill, Jordan, Molano, Olivia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Neuroscience
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9448854/
https://www.ncbi.nlm.nih.gov/pubmed/36090793
http://dx.doi.org/10.3389/fncel.2022.941031

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9448854/
https://www.ncbi.nlm.nih.gov/pubmed/36090793
http://dx.doi.org/10.3389/fncel.2022.941031

Ejemplares similares